麻豆传媒

Two-thirds of patients progression free at 6 months with zanidatamab, palbociclib, fulvestrant

No difference for survival outcomes for annual versus around every 2 years

However, the surgery did reduce risk of contralateral breast cancer

Local recurrence rate of 1% at 5 years in women ages 50-69 with genomically low-risk disease

Datopotamab deruxtecan was safe and boosted quality of life

But better safety profile versus continued pembrolizumab plus chemotherapy

Younger age, embryo/oocyte cryopreservation at diagnosis tied to an increased chance of pregnancy

Promising early results with pembrolizumab, nivolumab but event-free survival data still pending

Neoadjuvant administration of immunotherapy remains the preferred approach

Study showed no increase in disease progression when omitting regional nodal irradiation

Adding agent to T-DM1 resulted in 2-month progression-free survival improvement

Enthusiasm tempered by immune-related adverse events, diabetes with PD-1/LAG-3 combination

First comparison of targeted sentinel node assessment shows no difference in recurrence rates

In phase III trial, capivasertib benefited patients with or without AKT pathway alterations